Renaissance Capital logo

Esperion Therapeutics Priced, Nasdaq: ESPR

Developing a treatment for elevated levels of low-density lipoprotein cholesterol.

Industry: Health Care

First Day Return: +3.6%

Developing a treatment for elevated levels of low-density lipoprotein cholesterol.

Esperion Therapeutics (ESPR) Performance

Created with Highcharts 10.3.2Chart context menuESPR vs. IPO Index (IPOUSA)2014201520162017201820192020202120222023202420250%+ 200%+ 400%-200%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index